Pinned Tweet
Can we de-escalate ICIs in NSCLC?💡
Are we ready to reduce financial and patients' tox?🔎
Honoured to work on this topic with terrific colleagues
@HendriksLizza @JordiRemon @JessicaMenis @g_mountzios @BenjaminBesseMD @MarianaBrandao0 @NReguart @MartinaBortolot
Are we ready to reduce financial and patients' tox?🔎
Honoured to work on this topic with terrific colleagues
@HendriksLizza @JordiRemon @JessicaMenis @g_mountzios @BenjaminBesseMD @MarianaBrandao0 @NReguart @MartinaBortolot
De-Escalation Strategies With ICIs in NSCLC: Do We Already Have Enough Evidence? @JCO_ASCO
Pleased to contribute to this great review led by @JordiRemon @GustaveRoussy @OncoAlert @g_mountzios @HendriksLizza @FCortiula @JessicaMenis @MarianaBrandao0 #LCSM ascopubs.org/doi/10.1200/JC…
0
5
13
1,095
Francesco Cortiula retweeted
Important data.
‼️ Landmark #lungcancer research published today in Cell
Scientists at the Francis Crick Institute and UCL have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis, works in never-smokers, and could identify who benefits from People with high levels of these proteins were the ones who actually benefited from a drug to damp that inflammation down, cutting their lung cancer risk nearly in half.
This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk.
doi.org/10.1016/j.cell…
#LCSM
0
11
27
4,129
Francesco Cortiula retweeted
ANVIL: ADJ Nivolumab not ⬆️DFS vs BSC in IB/III NSCLC even in high PDL1 Heterogenous data with ADJ IO. No quality of surgery & good staging (PET/🧠) across trials.
No tumor ➡️ADJ IO not work
Do These negative results raise concerns about Role of ADJ after NEOADJ CTIO?#ASCO26
No tumor ➡️ADJ IO not work
Do These negative results raise concerns about Role of ADJ after NEOADJ CTIO?#ASCO26
2
14
29
1,388
RT @JordiRemon: ALEX trial 1st L alectinib (vs crizo) not ⬆️OS but trial not powered for OS. The best drug first? living w/o disease PD and…
0
22
0
RT @JordiRemon: Zipalertinib in EGFRex20ins NSCLC reported 31% of intracranial ORR 🧠. Today crowded space of TKI for EGFRex20ins. New SoC?…
0
30
0
Francesco Cortiula retweeted
Session opens with a case of stage IIIB #NSCLC in a frail 76-year-old. The MDT recommends sequential chemoradiotherapy. @FCortiula asks:
❓Can we de-escalate without losing radical intent?
❓Can immunotherapy reduce toxicity?
❓Can we tailor treatment to response?
#ESMO25 #MedX
❓Can we de-escalate without losing radical intent?
❓Can immunotherapy reduce toxicity?
❓Can we tailor treatment to response?
#ESMO25 #MedX
0
2
1
102
Francesco Cortiula retweeted
Italian National Team at #WCLC2025 @AriMarinel @RobertoFerrara_ @Max_Cani @Gmazzaschi90 @pecci_federica1 @doctordegio @CarloGenova5 and many others 🇮🇹🍕
1
11
31
2,711
Francesco Cortiula retweeted
Discuss a wide range of case studies with leading experts! Access practical cancer IO insights at @sitcancer’s #virtual ACI: A Focus on Lung Cancers program Sept. 12. View topics: ow.ly/sn3c50WMRj5
@ChaftJamie @FCortiula @DrJNaidoo @drshieldsmd
#LearnACI
@ChaftJamie @FCortiula @DrJNaidoo @drshieldsmd
#LearnACI
0
3
5
744
Francesco Cortiula retweeted
Press release updates data for NVL-520, zidesamtinib, in #ROS1 NSCLC. In 117 pts who had prior TKI (half had 2+ TKIs), RR 44% with 78% ongoing after one year. Intracranial efficacy and active in ROS1 G2032R. Tolerability: discontinuation rate only 2%!
investors.nuvalent.com/2025-06-24-Nuv…
investors.nuvalent.com/2025-06-24-Nuv…
0
16
50
3,448
Francesco Cortiula retweeted
📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance.
#LungCancer #mNSCLC #ESMOGuidelines
🔗 ow.ly/v7nE50Wbqsf
#LungCancer #mNSCLC #ESMOGuidelines
🔗 ow.ly/v7nE50Wbqsf
0
15
26
3,087
Francesco Cortiula retweeted
📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved.
🔗 ow.ly/kzQF50Wa0lf
#LungCancer #mNSCLC #ESMOGuidelines
🔗 ow.ly/kzQF50Wa0lf
#LungCancer #mNSCLC #ESMOGuidelines
0
18
37
7,788
Francesco Cortiula retweeted
#ASCO25 Developmental Therapeutics CSS🔥
Ph III DELLI trial: ultra-low dose nivo in 2L all solid tumors v chemo @VanitaNoronha @TataMemorial:
- 500pts
- OS HR 0.80 (p=0.02, NS primary endpt HR 0.75)
- no diff in PFS/ORR/tox
A brave trial, next step evaluate chemoIO? @asco
Ph III DELLI trial: ultra-low dose nivo in 2L all solid tumors v chemo @VanitaNoronha @TataMemorial:
- 500pts
- OS HR 0.80 (p=0.02, NS primary endpt HR 0.75)
- no diff in PFS/ORR/tox
A brave trial, next step evaluate chemoIO? @asco
0
5
19
849
Francesco Cortiula retweeted
Why is CM816 so important? After @FordePatrick beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…
5
30
98
16,730
Francesco Cortiula retweeted
#ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.
6
37
115
15,541
Francesco Cortiula retweeted
IMforte: lurbinectedin + atezo maintenance ES-SCLC
✅ ⬆️ mPFS 5.4 v 2.1m, HR 0.54
✅ ⬆️ mOS 13.2 v 10.6m, HR 0.73
✅ ⬆️ ORR 19% v 10%
🔺Gr3+ AE 25% v 5%
🔺 Myelosupression, N&V, fatigue
🤔 Active combo, at cost of toxicity
🤔 OS impressive = 16m from diagnosis
#LCSM #ASCO25
✅ ⬆️ mPFS 5.4 v 2.1m, HR 0.54
✅ ⬆️ mOS 13.2 v 10.6m, HR 0.73
✅ ⬆️ ORR 19% v 10%
🔺Gr3+ AE 25% v 5%
🔺 Myelosupression, N&V, fatigue
🤔 Active combo, at cost of toxicity
🤔 OS impressive = 16m from diagnosis
#LCSM #ASCO25
0
14
31
2,777
Francesco Cortiula retweeted
Fascinating paper @NatureCancer on mechanisms of resistance to TIL in NSCLC:
- serial multiomic analysis, 16pt TIL trial
- subclonal neoAg lost at progression
- LOH of pMHC in KRAS-specific Tcells at progression
@BenCreelan @MoffittNews @OncoAlert #LCSM nature.com/articles/s4301…
- serial multiomic analysis, 16pt TIL trial
- subclonal neoAg lost at progression
- LOH of pMHC in KRAS-specific Tcells at progression
@BenCreelan @MoffittNews @OncoAlert #LCSM nature.com/articles/s4301…
2
19
67
4,692
Francesco Cortiula retweeted
In @JTOonline #BRAF-mutated #NSCLC: bit.ly/JTO_BRAF
📊 1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows:
➖ Similar OS outcomes
➖ PD-L1 status & gender influence prognosis
🎯 Personalization > one-size-fits-all
@LungCancerRx @oncodaily @OncBrothers
📊 1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows:
➖ Similar OS outcomes
➖ PD-L1 status & gender influence prognosis
🎯 Personalization > one-size-fits-all
@LungCancerRx @oncodaily @OncBrothers
2
12
45
4,077
Congrats to all the authors for this great collaborative effort🏆
ICI retreatment after durvalumab for relapsed stage III NSCLC should be offered to selected patients💥📢
These results also confirm our previous findings🎯
@HendriksLizza
@AndrearicFili
ejcancer.com/article/S0959-…
ICI retreatment after durvalumab for relapsed stage III NSCLC should be offered to selected patients💥📢
These results also confirm our previous findings🎯
@HendriksLizza
@AndrearicFili
ejcancer.com/article/S0959-…
Real world outcomes in pts with relapse after durvalumab consolidation post CRT for stage III NSCLC @LungCaJournal. With chemo-immunotherapy, PFS 12m; with platinum-based chemo alone, PFS 4.1m; non-platinum based chemo PFS 2.7m; targeted therapy PFS 6m.
lungcancerjournal.info/article/S0169-…
0
3
9
689
Francesco Cortiula retweeted
Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is it better than CT+Ami or ADC? Hwr, it is a chemofree strategy and other treatments could be applied later #ELCC25
0
33
77
5,311